Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Jr. Michael Conick Hanley sold 2,896 shares of the business’s stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $26.48, for a total transaction of $76,686.08. Following the completion of the transaction, the chief operating officer owned 17,729 shares in the company, valued at $469,463.92. The trade was a 14.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Jr. Michael Conick Hanley also recently made the following trade(s):
- On Monday, November 16th, Jr. Michael Conick Hanley sold 70,000 shares of Alto Neuroscience stock. The shares were sold at an average price of $27.68, for a total transaction of $1,937,600.00.
- On Tuesday, November 17th, Jr. Michael Conick Hanley sold 2,104 shares of Alto Neuroscience stock. The stock was sold at an average price of $26.82, for a total transaction of $56,429.28.
Alto Neuroscience Stock Performance
Shares of ANRO stock traded up $0.85 during trading on Wednesday, hitting $25.77. 986,145 shares of the stock traded hands, compared to its average volume of 597,641. The company has a quick ratio of 18.12, a current ratio of 18.12 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average price is $25.83 and its 200-day moving average price is $24.79. Alto Neuroscience, Inc. has a 52-week low of $12.51 and a 52-week high of $37.48.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.13. Analysts anticipate that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current year.
Analyst Upgrades and Downgrades
ANRO has been the subject of a number of research analyst reports. Wedbush increased their price target on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a report on Thursday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Finally, BTIG Research reiterated a “buy” rating and set a $37.00 price target on shares of Alto Neuroscience in a research report on Wednesday, November 11th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.88.
Get Our Latest Research Report on ANRO
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the company. Quantinno Capital Management LP raised its position in Alto Neuroscience by 1.4% in the 1st quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after purchasing an additional 490 shares in the last quarter. Sterling Capital Management LLC grew its position in shares of Alto Neuroscience by 1,045.7% during the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock worth $27,000 after buying an additional 962 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Alto Neuroscience by 48,581.8% during the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock worth $137,000 after buying an additional 5,344 shares during the period. Renaissance Technologies LLC increased its stake in shares of Alto Neuroscience by 6.3% during the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after buying an additional 6,100 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Alto Neuroscience by 26.1% during the first quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock worth $884,000 after buying an additional 8,148 shares during the period.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Further Reading
- Five stocks we like better than Alto Neuroscience
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
